Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare TechnologiesBOM:539871 -0.91%83 Cyclically Adjusted PB Ratio is 14.61 as of Sep. 16, 2026, which is 50% above its 10-year median of 9.72. GuruFocus rates BOM:539871 with a GF Score™ of 83/100 and a GF Value™ of ₹430.61 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 127 Medical Diagnostics & Research companies, Thyrocare Technologies ranks worse than 787400.79% on this metric.
The historical rank and industry rank for Thyrocare Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Thyrocare Technologies's highest Cyclically Adjusted PB Ratio was 15.02. The lowest was 6.53. And the median was 9.72.
BOM:539871's Cyclically Adjusted PB Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.72 * Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Thyrocare Technologies's adjusted book value per share data for the three months ended in Jun. 2026 was ₹0.000. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹36.93 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Thyrocare Technologies (BOM:539871) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thyrocare Technologies Cyclically Adjusted PB Ratio Related Terms
Thyrocare Technologies Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies Cyclically Adjusted PB Ratio Chart
BOM:539871 vs TMO, DHR, NTRA: Cyclically Adjusted PB Ratio Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Cyclically Adjusted PB Ratio falls into.
Thyrocare Technologies Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 14.61 mean?
Thyrocare Technologies (BOM:539871) has a Cyclically Adjusted PB Ratio of 14.61 as of Sep. 16, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Thyrocare Technologies and its competitors. This is 50% above median its historical median of 9.72. Over the past decade, Thyrocare Technologies' Cyclically Adjusted PB Ratio has ranged from 6.53 to 15.02. According to the industry distribution chart, Thyrocare Technologies ranks #999999 out of 127 companies in the Medical Diagnostics & Research industry.
Is Thyrocare Technologies' Cyclically Adjusted PB Ratio too high?
Thyrocare Technologies' current Cyclically Adjusted PB Ratio of 14.61 is 50% above median its 10-year median of 9.72. Over the past 10 years, this metric has ranged from a low of 6.53 to a high of 15.02. The Medical Diagnostics & Research industry median Cyclically Adjusted PB Ratio is 1.72. Thyrocare Technologies' value of 14.61 is 749.4% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #999999 out of 127 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Cyclically Adjusted PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #999999 out of 127 companies for Cyclically Adjusted PB Ratio. This places Thyrocare Technologies in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.72. Thyrocare Technologies' value of 14.61 is 749.4% above this benchmark. Historically, Thyrocare Technologies' own Cyclically Adjusted PB Ratio has ranged from 6.53 to 15.02 over the past decade. While the company's 10-year median is 9.72 vs. the industry median of 1.72, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PB Ratio among Medical Diagnostics & Research companies is 1.72, based on 127 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current Cyclically Adjusted PB Ratio of 14.61 is 749.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PB Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Cyclically Adjusted PB Ratio is 14.61, which is 50% above median its own 10-year median of 9.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (BOM:539871) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹430.61, compared to a current price of ₹539.65 — trading 25.3% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 14.61, which is 50% above median its 10-year median of 9.72 and 749.4% above the Medical Diagnostics & Research industry median of 1.72. Thyrocare Technologies' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Thyrocare Technologies (BOM:539871), the current Cyclically Adjusted PB Ratio is 14.61 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (BOM:539871) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹539.65 is trading 25.3% above its estimated GF Value™ of ₹430.61.
GuruFocus considers Thyrocare Technologies to be Modestly Overvalued.
Key valuation signals for BOM:539871:
Cyclically Adjusted PB Ratio: 14.61 (50% above median its 10-year median of 9.72)
GF Value™: ₹430.61 vs. price of ₹539.65 (25.3% above fair value)
Industry Position: 749.4% above the Medical Diagnostics & Research median (#999999 of 127)
No single metric tells the full story. See the BOM:539871 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
83GF Score
Get the complete analysis for BOM:539871
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539871 has been successfully added to your 
